» Articles » PMID: 34834357

As a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

Abstract

Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only have a limited ability to predict which patients are more likely to develop this severe toxicity. To identify novel predictive genes, we conducted a two-stage genome-wide association study in epirubicin-treated BC patients. In the discovery phase, we genotyped over 700,000 single nucleotide variants in a cohort of 227 patients. The most interesting finding was rs62134260, located 4kb upstream of (OR = 5.76, P = 2.23 × 10). We replicated this association in a validation cohort of 123 patients (P = 0.021). This variant regulates the expression of , a gene that encodes a mitochondrial DNA-directed RNA polymerase, responsible for mitochondrial gene expression. Individuals harbouring the risk allele had a decreased expression of in heart tissue that may cause an impaired capacity to maintain a healthy mitochondrial population in cardiomyocytes under stressful conditions, as is treatment with epirubicin. This finding suggests a novel molecular mechanism involved in the development of AIC and may improve our ability to predict patients who are at risk.

Citing Articles

DNA damage-associated protein co-expression network in cardiomyocytes informs on tolerance to genetic variation and disease.

Johnson O, Paul S, Gutierrez J, Russell W, Ward M bioRxiv. 2024; .

PMID: 39185220 PMC: 11343126. DOI: 10.1101/2024.08.14.607863.


Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63.

Martinez-Campelo L, Blanco-Verea A, Lopez-Fernandez T, Martinez-Monzonis A, Buno A, Mazon P Sci Rep. 2024; 14(1):18413.

PMID: 39117733 PMC: 11310459. DOI: 10.1038/s41598-024-69064-5.


Integrated analysis of lactate-related genes identifies POLRMT as a novel marker promoting the proliferation, migration and energy metabolism of hepatocellular carcinoma via Wnt/β-Catenin signaling.

Wang H, Zhang Y, Du S Am J Cancer Res. 2024; 14(3):1316-1337.

PMID: 38590398 PMC: 10998737. DOI: 10.62347/ZTTG4319.


Anthracycline Toxicity: Light at the End of the Tunnel?.

Cejas R, Petrykey K, Sapkota Y, Burridge P Annu Rev Pharmacol Toxicol. 2023; 64():115-134.

PMID: 37788492 PMC: 11260185. DOI: 10.1146/annurev-pharmtox-022823-035521.


Meta-analysis of integrated ChIP-seq and transcriptome data revealed genomic regions affected by estrogen receptor alpha in breast cancer.

Piryaei Z, Salehi Z, Ebrahimie E, Ebrahimi M, Kavousi K BMC Med Genomics. 2023; 16(1):219.

PMID: 37715225 PMC: 10503144. DOI: 10.1186/s12920-023-01655-z.


References
1.
Hertz D, Caram M, Kidwell K, Thibert J, Gersch C, Seewald N . Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016; 17(3):231-40. PMC: 5558515. DOI: 10.2217/pgs.15.162. View

2.
Raj S, Franco V, Lipshultz S . Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 2014; 16(6):315. DOI: 10.1007/s11936-014-0315-4. View

3.
Yang X, Li G, Guan M, Bapat A, Dai Q, Zhong C . Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021; 8:651269. PMC: 8213036. DOI: 10.3389/fcvm.2021.651269. View

4.
Gyongyosi M, Lukovic D, Zlabinger K, Spannbauer A, Gugerell A, Pavo N . Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovasc Res. 2019; 116(5):970-982. DOI: 10.1093/cvr/cvz192. View

5.
Holmgren G, Synnergren J, Bogestal Y, Ameen C, Akesson K, Holmgren S . Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 2014; 328:102-11. PMC: 4326176. DOI: 10.1016/j.tox.2014.12.018. View